Building Biotech: How Nigeria can become the Vaccine Powerhouse in Africa
Posted on 11 Jun 2026
Nigeria currently imports every vaccine it uses, yet it has the political will, the regulatory foundations, and the scientific talent to change that. However, the country's path to self-sufficiency is far from straightforward, with cold chain failures, overlapping regulatory responsibilities, and a workforce that still needs to be built from the ground up. Our own Lee Smith, alongside researcher Oyeronke Oyebanji, shared their insights with BioProcess International on what it will truly take to get vaccines manufactured and delivered at scale.
View more blog posts
01
Live Attenuated Viral Vaccines Advancements
Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe.
02
Hope for Chlamydia STI Vaccine After Promising Initial Results
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials.
03
Gene Therapy for Rare Disorders
Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy.
04
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
CEPI awards US$21 million to Themis Bioscience.
05
GreyRigge Associates partners with NG Bio to accelerate VC investment
NG Bio and GreyRigge Associates Announce Strategic Partnership to Advance Biotech Innovation
06
Building Biotech: How Nigeria can become the Vaccine Powerhouse in Africa
Lee Smith and Oyeronke Oyebanji sat down with BioProcess Insider to discuss the vaccine development and delivery practices in Nigeria: the good, the bad, and the path forward.
07
Greyrigge Associates partner with SciPot Consultancy
GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy
08
Building Biotech: Being ready for AI
AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.
09
Building Biotech: How COVID-19 changed development forever
The COVID-19 pandemic transformed vaccine development by compressing timelines from decades to months, proving that rapid innovation is possible through parallel development, adaptive regulation, and unprecedented global equity.
010
Building Biotech: Animal Models and Beyond - What's Next?
Animal models have long underpinned vaccine development by enabling preclinical evaluation of immunogenicity, efficacy, safety, and dose selection, and they remain integral to regulatory submissions and certain approval pathways such as the FDA Animal Rule.